AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18199095 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-carnitine supplementation
Number of subjects: 0
Study 16050414 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 16050414 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II blockers
Number of subjects: 0
Study 16050414 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant use of statins and angiotensin II blockers
Number of subjects: 0
Study 14500112 — intervention group
Group type: EXPERIMENTAL
Intervention: Light therapy
Number of subjects: 19
Study 14500112 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study 10652037 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 16
Study 10652037 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg
Number of subjects: 16
Study 10652037 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg
Number of subjects: 16
Study 10652037 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg
Number of subjects: 16
Study 10652037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8540513 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal oxygen (2 L/min)
Number of subjects: 30
Study 8540513 — intervention group
Group type: COMPARATOR
Intervention: Room air (no oxygen)
Number of subjects: 30
Study 2178334 — intervention group
Group type: COMPARATOR
Intervention: dideoxycytidine (ddC) at 0.1 and 1 microM
Number of subjects: 0
Study 2178334 — intervention group
Group type: COMPARATOR
Intervention: dideoxyinosine (ddI) at 0.2 to 50 microM
Number of subjects: 0
Study 2178334 — intervention group
Group type: COMPARATOR
Intervention: dideoxyinosine (ddI) at 2 microM
Number of subjects: 0
Study 2178334 — intervention group
Group type: COMPARATOR
Intervention: dideoxyinosine (ddI)
Number of subjects: 0
Study 7031982 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin fraction
Number of subjects: 6
Study 7031982 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 6
Study 7031982 — intervention group
Group type: COMPARATOR
Intervention: High molecular weight heparin fraction
Number of subjects: 6
Study 7031982 — intervention group
Group type: EXPERIMENTAL
Intervention: All heparin preparations
Number of subjects: 6
Study 31551227 — intervention group
Group type: EXPERIMENTAL
Intervention: External application of Liuhe Dan
Number of subjects: 160
Study 31551227 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing methods (Control)
Number of subjects: 160
Study 28237635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 92
Study 28237635 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 92
Study 28237635 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 92
Study 25765966 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant administration of ProQuad(®) and hexavalent vaccine
Number of subjects: 0
Study 25765966 — intervention group
Group type: EXPERIMENTAL
Intervention: ProQuad(®) alone
Number of subjects: 0
Study 25765966 — intervention group
Group type: COMPARATOR
Intervention: Hexavalent vaccine alone
Number of subjects: 0
Study 22956676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-based compassion training (CBCT)
Number of subjects: 21
Study 22956676 — intervention group
Group type: COMPARATOR
Intervention: Health discussion control group
Number of subjects: 21
Study 22069974 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopy assisted percutaneous internal fixation
Number of subjects: 58
Study 22069974 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation
Number of subjects: 58
Study 19680681 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise (four 2-min isometric contractions at 30% MVC)
Number of subjects: 18
Study 19680681 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise
Number of subjects: 18
Study 19680681 — intervention group
Group type: COMPARATOR
Intervention: Time-matched control condition
Number of subjects: 18
Study 17257728 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral presentations of distractors (either a word or a pseudoword)
Number of subjects: 0
Study 17257728 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral presentations with perceptual distractors (sequences of the letter 'x')
Number of subjects: 0
Study 17257728 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of performance patterns on trials with perceptual and lexical distractors
Number of subjects: 0
Study 15531055 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled loading protocol (three, 3-min posterior to anterior normalized loads directed to the posterior calf)
Number of subjects: 0
Study 15531055 — intervention group
Group type: COMPARATOR
Intervention: Control limb (one knee served as control)
Number of subjects: 0
Study 11320361 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated TPA with reduced heparin dose mid-trial
Number of subjects: 0
Study 11320361 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated TPA with lowest heparin dose
Number of subjects: 0
Study 11320361 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-bolus TNK-TPA and lanoteplase with reduced heparin dose
Number of subjects: 0
Study 11320361 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose, weight-adjusted heparin regimen (60 U/kg bolus; maximum, 4000 U; 12 U/kg per hour infusion; maximum, 1000 U/h)
Number of subjects: 0
Study 9447478 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day for 3 days)
Number of subjects: 10
Study 9447478 — intervention group
Group type: COMPARATOR
Intervention: Thiothixene (20 mg single oral dose)
Number of subjects: 10
Study 8070160 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet for 3 weeks
Number of subjects: 17
Study 8070160 — intervention group
Group type: COMPARATOR
Intervention: Control soup (milk, meat, fish, shellfish, orange, pineapples, tomatoes, peas, flour of wheat and corn) for 3 weeks
Number of subjects: 17
Study 2970203 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (30 mg daily)
Number of subjects: 70
Study 2970203 — intervention group
Group type: COMPARATOR
Intervention: Mianserin (60 mg daily)
Number of subjects: 70
Study 2970203 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 70
Study 31726241 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (disappointed before cognitive task)
Number of subjects: 148
Study 31726241 — intervention group
Group type: COMPARATOR
Intervention: Control group (not disappointed before cognitive task)
Number of subjects: 148
Study 31726241 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (children expressing appreciative positive emotions)
Number of subjects: 148
Study 31726241 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (children expressing negative emotions or no reaction)
Number of subjects: 148
Study 29788487 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 333
Study 29788487 — intervention group
Group type: COMPARATOR
Intervention: Weight loss
Number of subjects: 333
Study 28902705 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D (120,000 IU/monthly)
Number of subjects: 102
Study 28902705 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose vitamin D (60,000 IU/monthly)
Number of subjects: 102
Study 28902705 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard/control dose vitamin D (18,000 IU/monthly)
Number of subjects: 102
Study 26303780 — intervention group
Group type: EXPERIMENTAL
Intervention: MFGM (1 g)
Number of subjects: 14
Study 26303780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 24030722 — intervention group
Group type: EXPERIMENTAL
Intervention: Campaign materials (mainly posters, brochures, and advertisements on local media, plus a newsletter on local antibiotic resistance targeted at doctors and pharmacists)
Number of subjects: 1150000
Study 24030722 — intervention group
Group type: EXPERIMENTAL
Intervention: Campaign materials
Number of subjects: 1150000
Study 21132310 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary pyruvate (300 mmol/L, 360 ml/h)
Number of subjects: 0
Study 21132310 — intervention group
Group type: COMPARATOR
Intervention: Standard care with primary PCI and intra‐aortic balloon pump (IABP)
Number of subjects: 0
Study 18300256 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel every 3 weeks (75 mg/m2)
Number of subjects: 118
Study 18300256 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel weekly (35 mg/m2)
Number of subjects: 118
Study 18300256 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel every 3 weeks
Number of subjects: 118
Study 18300256 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel weekly
Number of subjects: 118
Study 16966982 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief counseling
Number of subjects: 187
Study 16966982 — intervention group
Group type: COMPARATOR
Intervention: Simple advice
Number of subjects: 187
Study 16966982 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 187
Study 15115076 — intervention group
Group type: EXPERIMENTAL
Intervention: Dot-ELISA using FG 27 antigen
Number of subjects: 0
Study 15115076 — intervention group
Group type: COMPARATOR
Intervention: Control sera from patients with other parasitic infections and healthy volunteers
Number of subjects: 0
Study 11125778 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent Transitions Program (ATP)
Number of subjects: 0
Study 8807169 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 80
Study 8807169 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 20 micrograms.kg-1
Number of subjects: 80
Study 8807169 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms.kg-1
Number of subjects: 80
Study 8807169 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 80 micrograms.kg-1
Number of subjects: 80
Study 1384256 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP-ABVD (MOPP: Mustine, Vincristine, Procarbazine, Prednisone; ABVD: Adriamycin, Bleomycin, Vinblastine, Dacarbazine)
Number of subjects: 54
Study 1384256 — intervention group
Group type: COMPARATOR
Intervention: MOPP-ABVD-CEM (CEM: Carmustine, Etoposide, methyl-GAG)
Number of subjects: 54
Study 6532147 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.6 g of ethanol per kg of body weight)
Number of subjects: 40
Study 6532147 — intervention group
Group type: COMPARATOR
Intervention: Non-alcohol treatments
Number of subjects: 40
Study 31325144 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab/Irinotecan (BEV/IRI)
Number of subjects: 121
Study 31325144 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide (TMZ)
Number of subjects: 121
Study 29806181 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective tissue graft (test group, n=30)
Number of subjects: 60
Study 29806181 — intervention group
Group type: COMPARATOR
Intervention: No connective tissue graft (control group, n=30)
Number of subjects: 60
Study 29806181 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 26285178 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg followed by misoprostol 800 mcg vaginally 6-8 or 23-25 hours later
Number of subjects: 2160
Study 26285178 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg followed by misoprostol 800 mcg vaginally < 15 min or 23-25 hours later
Number of subjects: 2160
Study 26285178 — intervention group
Group type: EXPERIMENTAL
Intervention: Parity of five or more deliveries
Number of subjects: 2160
Study 26285178 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age of 8 weeks or more
Number of subjects: 2160
Study 26285178 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of 20 years or younger
Number of subjects: 2160
Study 25411292 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fat quality (ratio of unsaturated to saturated fats)
Number of subjects: 2
Study 25411292 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary lipid quality
Number of subjects: 2
Study 22987495 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy
Number of subjects: 100
Study 22987495 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoanalytic therapy
Number of subjects: 100
Study 22987495 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic therapy
Number of subjects: 100
Study 21275357 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic leg brace
Number of subjects: 15
Study 21275357 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation (No brace)
Number of subjects: 15
Study 16806873 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-to-Stand Test (STST)
Number of subjects: 53
Study 16806873 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 min walk test (6MWT)
Number of subjects: 53
Study 16806873 — intervention group
Group type: COMPARATOR
Intervention: 6MWT
Number of subjects: 53
Study 16806873 — intervention group
Group type: EXPERIMENTAL
Intervention: STST and 6MWT
Number of subjects: 53
Study 16806873 — intervention group
Group type: EXPERIMENTAL
Intervention: STST
Number of subjects: 53
Study 15653703 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HDMTX) 4 g/m² followed by leucovorin rescue
Number of subjects: 154
Study 15653703 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 154
Study 12040528 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab + interferon-α2a
Number of subjects: 20
Study 12040528 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab + granulocyte-colony stimulating factor
Number of subjects: 20
Study 12040528 — intervention group
Group type: COMPARATOR
Intervention: Rituximab monotherapy
Number of subjects: 20
Study 9860150 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NAME 1 mg x kg(‐1) x h(‐1) for 12 hours
Number of subjects: 9
Study 7719244 — intervention group
Group type: EXPERIMENTAL
Intervention: Various biologic and chemotherapeutic agents for hairy-cell leukemia
Number of subjects: 0
Study 7719244 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 2692651 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly 20 mg doses of doxorubicin
Number of subjects: 143
Study 30168357 — intervention group
Group type: COMPARATOR
Intervention: Inverted pendulum model during level walking in able-bodied participants
Number of subjects: 25
Study 30168357 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted pendulum model during level walking in individuals with unilateral transfemoral amputation
Number of subjects: 25
Study 29349976 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-week irrigation group
Number of subjects: 23
Study 29349976 — intervention group
Group type: COMPARATOR
Intervention: One-week irrigation group
Number of subjects: 23
Study 25440999 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg orally once a day for 12 weeks
Number of subjects: 62
Study 25440999 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 5 mg orally once a day for 12 weeks
Number of subjects: 62
Study 25440999 — intervention group
Group type: COMPARATOR
Intervention: Comparison between telmisartan and lisinopril
Number of subjects: 62
Study 24364174 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally displaced flap plus amnion allograft
Number of subjects: 22
Study 24364174 — intervention group
Group type: COMPARATOR
Intervention: Coronally displaced flap plus connective tissue graft
Number of subjects: 22
Study 21502541 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 22
Study 21502541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 19496776 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2000 mg daily)
Number of subjects: 24
Study 19496776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 16500321 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix (0.25 mg SC) with half dose of recombinant FSH for 2 days until hCG administration
Number of subjects: 67
Study 16500321 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 32) continued recombinant FSH until hCG administration
Number of subjects: 67
Study 12795584 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral day treatment plus abstinence-contingent housing and work therapy
Number of subjects: 0
Study 12795584 — intervention group
Group type: COMPARATOR
Intervention: Behavioral day treatment only
Number of subjects: 0
Study 10856892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous TRH administration
Number of subjects: 20
Study 10856892 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal TRH administration
Number of subjects: 20
Study 10856892 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral TRH administration
Number of subjects: 20
Study 10856892 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH stimulation (30 min)
Number of subjects: 20
Study 10856892 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH stimulation (60 min)
Number of subjects: 20
Study 10856892 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH stimulation (180 min)
Number of subjects: 20
Study 10856892 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH stimulation (120 min)
Number of subjects: 20
Study 10856892 — intervention group
Group type: COMPARATOR
Intervention: Basal TSH
Number of subjects: 20
Study 10856892 — intervention group
Group type: COMPARATOR
Intervention: Pituitary standard TSH (IRP 80/558)
Number of subjects: 20
Study 9168167 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (1 mg for 1 day)
Number of subjects: 4
Study 9168167 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (1000 mg per day for 5 days)
Number of subjects: 4
Study 9168167 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 4
Study 9168167 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam and Vigabatrin
Number of subjects: 4
Study 8251283 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 80
Study 8251283 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 80
Study 3510282 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous cyclic therapy with dibromodulcitol, doxorubicin, vincristine, tamoxifen, and fluoxymesterone (DAVTH)
Number of subjects: 97
Study 3510282 — intervention group
Group type: COMPARATOR
Intervention: DAVTH alternating with cyclophosphamide, methotrexate, 5‐fluorouracil, and prednisone (CMFP)
Number of subjects: 97
Study 3510282 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pretreatment CEA levels
Number of subjects: 97
Study 3510282 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated pretreatment CEA levels
Number of subjects: 97
Study 3510282 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial CEA levels during therapy
Number of subjects: 97
Study 3510282 — intervention group
Group type: EXPERIMENTAL
Intervention: Rising CEA levels
Number of subjects: 97
Study 3510282 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with unknown ER status
Number of subjects: 97
Study 3510282 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous DAVTH therapy
Number of subjects: 97
Study 29807301 — intervention group
Group type: COMPARATOR
Intervention: New pointe shoes
Number of subjects: 15
Study 29807301 — intervention group
Group type: EXPERIMENTAL
Intervention: Worn pointe shoes (>20 hours wear)
Number of subjects: 15
Study 26305603 — intervention group
Group type: EXPERIMENTAL
Intervention: iPad‐delivered multiple behavior tailored intervention (Healthy Pregnancy: Step by Step)
Number of subjects: 335
Study 26305603 — intervention group
Group type: COMPARATOR
Intervention: Usual care (March of Dimes brochures)
Number of subjects: 335
Study 24884602 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab low dose (0.03 mg/kg i.v. once, N = 20)
Number of subjects: 1026
Study 24884602 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab intermediate dose (0.1 and 0.3 mg/kg i.v. once, 5 and 15 mg s.c. monthly, N = 247)
Number of subjects: 1026
Study 24884602 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab medium dose (1.5 mg/kg i.v. once, 50 mg s.c. monthly and 150 mg s.c. once, N = 268)
Number of subjects: 1026
Study 24884602 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab high dose (10 mg/kg i.v. once and 150 mg s.c. monthly, N = 137)
Number of subjects: 1026
Study 24884602 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 354)
Number of subjects: 1026
Study 23102995 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan plus Calcium Channel Blocker (CCB)
Number of subjects: 58
Study 23102995 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan plus Diuretic
Number of subjects: 58
Study 23102995 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan plus CCB
Number of subjects: 58
Study 20634749 — intervention group
Group type: EXPERIMENTAL
Intervention: Hold Breath (HB) technique
Number of subjects: 30
Study 20634749 — intervention group
Group type: COMPARATOR
Intervention: Controlled Breathing technique
Number of subjects: 30
Study 18607829 — intervention group
Group type: EXPERIMENTAL
Intervention: sFlt-1:PlGF ratio
Number of subjects: 104
Study 18607829 — intervention group
Group type: EXPERIMENTAL
Intervention: endoglin
Number of subjects: 104
Study 18607829 — intervention group
Group type: EXPERIMENTAL
Intervention: sFlt-1
Number of subjects: 104
Study 18607829 — intervention group
Group type: EXPERIMENTAL
Intervention: PlGF
Number of subjects: 104
Study 18607829 — intervention group
Group type: EXPERIMENTAL
Intervention: sFlt-1:PlGF
Number of subjects: 104
Study 16080670 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency sinus excision
Number of subjects: 35
Study 16080670 — intervention group
Group type: COMPARATOR
Intervention: Excision and marsupialization
Number of subjects: 35
Study 12572787 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance education program for diarrhea and cholera case management
Number of subjects: 132
Study 12572787 — intervention group
Group type: COMPARATOR
Intervention: Control group (doctors and nurses not offered the course)
Number of subjects: 132
Study 10511389 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation
Number of subjects: 2609